Apyx Medical (NASDAQ:APYX) Price Target Cut to $3.00

Apyx Medical (NASDAQ:APYXGet Rating) had its price target reduced by research analysts at Piper Sandler to $3.00 in a report issued on Wednesday, Stock Target Advisor reports. Piper Sandler’s target price indicates a potential upside of 112.77% from the company’s previous close.

A number of other equities research analysts have also recently commented on the company. JMP Securities cut Apyx Medical from an “outperform” rating to a “market perform” rating in a research note on Thursday, November 10th. Lake Street Capital cut their target price on Apyx Medical from $18.00 to $10.00 in a research note on Friday, November 11th. Finally, Craig Hallum cut their target price on Apyx Medical to $10.00 in a research note on Wednesday.

Apyx Medical Trading Down 6.6 %

NASDAQ APYX opened at $1.41 on Wednesday. Apyx Medical has a 12 month low of $1.36 and a 12 month high of $17.50. The stock has a market cap of $48.78 million, a P/E ratio of -2.52 and a beta of 1.52. The stock’s fifty day moving average price is $4.48 and its 200-day moving average price is $5.77.

Insider Activity at Apyx Medical

In other Apyx Medical news, CEO Charles D. Goodwin II acquired 11,750 shares of the company’s stock in a transaction that occurred on Monday, August 29th. The shares were bought at an average cost of $5.96 per share, with a total value of $70,030.00. Following the completion of the transaction, the chief executive officer now directly owns 40,000 shares of the company’s stock, valued at approximately $238,400. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 11.60% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Cowen AND Company LLC lifted its holdings in Apyx Medical by 7.0% in the second quarter. Cowen AND Company LLC now owns 2,818,341 shares of the company’s stock valued at $16,515,000 after acquiring an additional 184,338 shares during the period. Archon Capital Management LLC lifted its holdings in Apyx Medical by 6.4% in the first quarter. Archon Capital Management LLC now owns 2,333,589 shares of the company’s stock valued at $15,238,000 after acquiring an additional 139,471 shares during the period. Vanguard Group Inc. lifted its holdings in Apyx Medical by 0.8% in the third quarter. Vanguard Group Inc. now owns 1,413,857 shares of the company’s stock valued at $6,349,000 after acquiring an additional 10,700 shares during the period. Invenire Partners LP lifted its holdings in Apyx Medical by 63.6% in the third quarter. Invenire Partners LP now owns 945,711 shares of the company’s stock valued at $4,246,000 after acquiring an additional 367,758 shares during the period. Finally, UBS Group AG lifted its holdings in Apyx Medical by 0.8% in the third quarter. UBS Group AG now owns 889,044 shares of the company’s stock valued at $3,992,000 after acquiring an additional 7,432 shares during the period. Institutional investors own 60.85% of the company’s stock.

Apyx Medical Company Profile

(Get Rating)

Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures.

Featured Stories

Stock Target Advisor logo

Receive News & Ratings for Apyx Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apyx Medical and related companies with MarketBeat.com's FREE daily email newsletter.